Details for New Drug Application (NDA): 204629
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.
Summary for 204629
Tradename: | JARDIANCE |
Applicant: | Boehringer Ingelheim |
Ingredient: | empagliflozin |
Patents: | 7 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 204629
Mechanism of Action | Sodium-Glucose Transporter 2 Inhibitors |
Suppliers and Packaging for NDA: 204629
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
JARDIANCE | empagliflozin | TABLET;ORAL | 204629 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0152 | 0597-0152-07 | 1 BOTTLE in 1 CARTON (0597-0152-07) / 7 TABLET, FILM COATED in 1 BOTTLE |
JARDIANCE | empagliflozin | TABLET;ORAL | 204629 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0152 | 0597-0152-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0597-0152-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
Approval Date: | Aug 1, 2014 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Feb 24, 2025 | ||||||||
Regulatory Exclusivity Use: | LABELING REVISIONS RELATED TO CLINICAL STUDIES | ||||||||
Regulatory Exclusivity Expiration: | Aug 18, 2024 | ||||||||
Regulatory Exclusivity Use: | REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION | ||||||||
Patent: | See Plans and Pricing | Patent Expiration: | Apr 3, 2034 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2 |
Complete Access Available with Subscription